Chikungunya Clinical Trials 2023

Chikungunya Clinical Trials 2023

Chikungunya research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in chikungunya clinical trials today.

Chikungunya Clinical Trials

Here are the 0 most popular medical studies for chikungunya

Popular filter options for chikungunya trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to chikungunya

What are the top hospitals conducting chikungunya research?

In the battle against chikungunya, a debilitating viral disease transmitted by mosquitoes, hospitals across the United States are stepping up to contribute to vital clinical trials. One such hospital is Accelerated Enrollment Solutions (AES) in Phoenix, which currently has one active chikungunya trial underway. Since its first recorded trial on this condition in 2020, AES has been dedicated to advancing our understanding of this disease and developing effective treatments. Similarly, AES in San Diego and Chicago have also joined the fight with their own ongoing trials for chikungunya.

Another institution making significant strides is ELITE Research Network located in Hallandale Beach. This research network prides itself on being at the forefront of medical innovation and currently has an active clinical trial for chikungunya. By undertaking such studies since 2021 when they initiated their inaugural examination into this particular illness, ELITE Research Network showcases its commitment to expanding knowledge about chikungunya.

Furthermore, Alliance for Multispecialty Research (AMR) based in Lexington is actively engaged in tackling chikungunya through clinical research initiatives as well. With one ongoing trial targeting this viral infection and two past trials dating back to 2020 marking their initial ventures into studying the disease's intricacies; AMR demonstrates dedication towards generating breakthroughs that will ultimately aid individuals affected by chikungunya.

These hospitals represent beacons of hope as researchers tirelessly work toward finding better ways to prevent and treat chikungunya infections through rigorous scientific investigations led by skilled medical professionals nationwide. Their collective efforts offer promise not only for those directly impacted but also potentially for populations worldwide susceptible to this vector-borne illness.

Which are the best cities for chikungunya clinical trials?

When it comes to chikungunya clinical trials, several cities in the United States have emerged as leading centers for research. Phoenix, Arizona; San Diego, California; Hallandale Beach, Florida; Chicago, Illinois; and Lexington, Kentucky, Illinois; and Lexington, Kentucky each host one active trial studying VLA1553 and other potential treatments. These cities offer individuals affected by chikungunya access to cutting-edge clinical trials that contribute to advancing our understanding of this disease and developing effective therapies.

Which are the top treatments for chikungunya being explored in clinical trials?

Clinical trials are paving the way for advancements in treating chikungunya, with VLA1553 emerging as a top contender. Currently, there is one active trial dedicated to exploring the potential of this treatment. Since its debut in 2018, VLA1553 has been involved in a total of four clinical trials focused on combating chikungunya. As researchers continue to investigate and refine these treatments, we move closer to finding effective solutions for those affected by this debilitating disease.

What are the most recent clinical trials for chikungunya?

The most recent clinical trial for chikungunya is focused on VLA1553. This innovative treatment, currently in Phase 3, shows promising potential to combat the effects of chikungunya virus infection. With its availability since April 2, 2021, this trial aims to provide valuable insights into the efficacy and safety of VLA1553 as a possible solution for individuals affected by chikungunya. Stay tuned for further updates on this groundbreaking study that may offer new hope in managing and preventing the spread of this debilitating disease.

What chikungunya clinical trials were recently completed?

Recently, several clinical trials focusing on chikungunya have achieved significant milestones, bringing us closer to potential treatments for this viral disease. Notably, Bavarian Nordic sponsored three completed trials that investigated the efficacy of CHIKV VLP with adjuvant. The latest trial was concluded in May 2022 and built upon previous studies conducted in October 2021 and September 2021. These advancements highlight the tireless efforts of researchers in their quest to combat chikungunya and provide hope for individuals affected by this debilitating illness.